Incyte Raises 2026 Sales View to $5.21B-$5.3B
Story updates
11:15:29 AM UTC
SquawkNews
Incyte reported third-quarter 2026 revenue of $1.56 billion, up 14% year over year, while GAAP results included a $784.8 million net loss, primarily reflecting a one-time research and development charge related to its Vega Therapeutics acquisition. The company raised its 2026 guidance for Opzelura…